Benevolent News Hub

NIAID trial shows baricitinib in combination with remdesivir reduces the recovery time in patients hospitalised with COVID-19, validating BenevolentAI’s AI-derived hypothesis.

BenevolentAI Director of Talent Acquisition and Development, Yasmina Rahiman, explores the power of coaching for leadership development in technology.

Research published in EMBO Molecular Medicine confirms AI predictions for anti-viral and anti-cytokine signalling effects of baricitinib in critically hospitalised COVID-19 patients

David Sinclair and colleagues review our recent publication in the EMBO Molecular Medicine Journal in support of our AI-derived hypothesis for a potential treatment of COVID-19.

“We need leaders with empathy who care about their fellow citizens and are prepared to work to end injustice and create opportunities for all". Our CEO Joanna Shields opens CogX 2020 sharing inspiration for the next decade.

To conclude Mental Health awareness week, we share some thoughts about the power of kindness and how building a culture of openness will help shape the future of business.

For Mental Health Awareness Week, BenevolentAI’s in-house yogis and bioinformaticians evaluated the scientific research behind the effect of yoga on mental health.

BenevolentAI announced that baricitinib is entering clinical testing as a potential COVID-19 treatment. Benevolent identified the drug using its AI drug discovery platform. The trial by Eli Lilly will investigate the drug’s efficacy and safety.

BenevolentAI today announced it has been selected for Tech Nation’s 2020 Future Fifty cohort. Our CEO Joanna Shields reflects on how joining forces with like-minded industry experts can serve as a powerful vehicle for transformation.

Our Senior Product Designer explores the design process at BenevolentAI where he builds user facing tools that help our scientists discover and develop new medicines.